• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $XTNT

    Xtant Medical Holdings Inc.

    Subscribe to $XTNT
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM Putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; and OsteoWrap that wraps around non-union fractures to assist with fusion, as well as used in conjunction with a hardware plate system. The company also provides 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. In addition, it processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Further, the company offers Certex spinal fixation system; Spider cervical plating system; Axle Interspinous Fusion System; Silex Sacroiliac joint fusion system; Xpress minimally invasive pedicle screw system; and Fortex Pedicle screw system. Additionally, it provides Calix for cervical and thoracolumbar applications, Axle-X interspinous fusion system, Irix-C cervical integrated fusion system, and Irix-A Lumbar integrated fusion system. The company was formerly known as Bacterin International Holdings, Inc. and changed its name to Xtant Medical Holdings, Inc. in July 2015. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.

    IPO Year:

    Exchange: AMEX

    Website: xtantmedical.com

    Recent Analyst Ratings for Xtant Medical Holdings Inc.

    DatePrice TargetRatingAnalyst
    12/5/2023$2.00Buy
    BTIG Research
    See more ratings

    Xtant Medical Holdings Inc. SEC Filings

    See more
    • Xtant Medical Holdings Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Results of Operations and Financial Condition, Changes in Control of Registrant, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Xtant Medical Holdings, Inc. (0001453593) (Filer)

      4/16/25 4:55:59 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13G filed by Xtant Medical Holdings Inc.

      SCHEDULE 13G - Xtant Medical Holdings, Inc. (0001453593) (Subject)

      4/16/25 2:11:44 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Xtant Medical Holdings Inc.

      SCHEDULE 13D/A - Xtant Medical Holdings, Inc. (0001453593) (Subject)

      4/14/25 7:09:38 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by Xtant Medical Holdings Inc.

      8-K - Xtant Medical Holdings, Inc. (0001453593) (Filer)

      4/11/25 7:00:33 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K filed by Xtant Medical Holdings Inc.

      10-K - Xtant Medical Holdings, Inc. (0001453593) (Filer)

      3/6/25 4:16:02 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Xtant Medical Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Xtant Medical Holdings, Inc. (0001453593) (Filer)

      3/6/25 4:10:29 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Xtant Medical Holdings Inc.

      10-Q - Xtant Medical Holdings, Inc. (0001453593) (Filer)

      11/12/24 4:15:42 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Xtant Medical Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Xtant Medical Holdings, Inc. (0001453593) (Filer)

      11/12/24 4:10:25 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Xtant Medical Holdings Inc.

      EFFECT - Xtant Medical Holdings, Inc. (0001453593) (Filer)

      9/12/24 12:15:07 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B3 filed by Xtant Medical Holdings Inc.

      424B3 - Xtant Medical Holdings, Inc. (0001453593) (Filer)

      9/11/24 5:12:23 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Xtant Medical Holdings Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Brandt Kevin D bought $49,837 worth of shares (41,670 units at $1.20), increasing direct ownership by 5% to 815,860 units (SEC Form 4)

      4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)

      11/17/23 4:42:41 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Xtant Medical Holdings Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on Xtant Medical with a new price target

      BTIG Research initiated coverage of Xtant Medical with a rating of Buy and set a new price target of $2.00

      12/5/23 8:12:02 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Xtant Medical Holdings Inc. Financials

    Live finance-specific insights

    See more

    Xtant Medical Holdings Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Xtant Medical to Issue First Quarter 2025 Financial Results on May 12, 2025

      BELGRADE, Mont., May 6, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic and woundcare disorders, today announced that it will release its financial results for the first quarter ended March 31, 2025, after the close of the financial markets on Monday, May 12, 2025. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Monday, May 12, 2025 at 4:30 PM ET to review results. Conference Details:Conference Date: Monday, May 12, 2025Conference Time: 4:30 PM ETConference dial-in: 888-506-0062International dial

      5/6/25 8:00:00 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Xtant Medical Reports Third Quarter 2024 Financial Results

      Third Quarter Revenue Growth of 12%Reaffirms Full Year 2024 Revenue Guidance of $116 Million to $120 MillionRepresenting Growth of 27% to 31% BELGRADE, MT / ACCESSWIRE / November 12, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the third quarter ended September 30, 2024.Third Quarter 2024 Financial HighlightsRevenue of $27.9 million, up 12%, compared to the prior year quarter; year to date revenue of $85.8 million, up 36% compared to prior year periodGross margin of 58.4% compared to 61.3% for the prior year quarterNet loss of $5.0 mi

      11/12/24 4:05:00 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Xtant Medical to Issue Third Quarter 2024 Financial Results on November 12, 2024

      BELGRADE, MT / ACCESSWIRE / November 7, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the third quarter ended September 30, 2024, after the close of the financial markets on Tuesday, November 12, 2024.Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Tuesday, November 12, 2024 at 4:30 PM ET to review results.Conference Details:Conference Date: Tuesday, November 12, 2024Conference Time: 4:30 PM ETConference dial-in: 888-999-3182International dial-in:

      11/7/24 10:45:00 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Xtant Medical to Host Second Quarter 2024 Financial Results Earnings Conference call on August 9, 2024

      BELGRADE, MT / ACCESSWIRE / August 8, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the second quarter ended June 30, 2024, after the close of the financial markets on Thursday, August 8, 2024.Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Friday, August 9, 2024, at 9:00 AM ET to review results.Conference Details:Conference Date: Friday, August 9, 2024Conference Time: 9:00 AM ETConference dial-in: 888-999-3182International dial-in: 848-280-6330Pas

      8/8/24 7:10:00 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Xtant Medical Reports Second Quarter 2024 Revenue Growth of 48%

      BELGRADE, MT / ACCESSWIRE / August 8, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the second quarter ended June 30, 2024.Second Quarter 2024 Financial HighlightsRevenue of $29.9 million, up 48%, compared to the prior year quarterGross margin of 62.1%, up 50 basis points, compared to the prior year quarterNet loss of $3.9 million compared to $2.2 million in the year ago quarterPositive Adjusted EBITDA; Adjusted EBITDA of $0.5 million compared to $0.1 million in the prior year quarterRecent Business HighlightsRecently launched two new

      8/8/24 7:05:00 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Xtant Medical Reports First Quarter 2024 Revenue Growth of 55% and Raises Full Year 2024 Revenue Guidance

      Expects Revenue for Full Year 2024 of $116 Million to $120 MillionBELGRADE, MT / ACCESSWIRE / May 15, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the first quarter ended March 31, 2024.First Quarter 2024 Financial HighlightsRevenue of $27.9 million, up 55%, compared to the prior year quarterGross margin of 62.1%, up 340 basis points, compared to the prior year quarterNet loss of $4.4 million compared to $2.1 million in the year ago quarterPositive Adjusted EBITDA; Adjusted EBITDA of $0.1 million compared to an Adjusted EBITDA loss of

      5/15/24 4:05:00 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Xtant Medical to Issue First Quarter 2024 Financial Results on May 15, 2024

      BELGRADE, MO / ACCESSWIRE / May 8, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the first quarter ended March 31, 2024, after the close of the financial markets on Wednesday, May 15, 2024.Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Wednesday, May 15 at 4:30 PM ET to review results.Conference Details:Conference Date: Wednesday, May 15, 2024Conference Time: 4:30 PM ETConference dial-in: 877-545-0523International dial-in: 973-528-0016Passcode: 69

      5/8/24 8:30:00 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Xtant Medical Announces Record Full Year 2023 Revenue of $91.3 Million

      Establishes Full Year 2024 Revenue Guidance of $112 Million - $116 Million BELGRADE, Mont., April 01, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the fourth quarter and year ended December 31, 2023. "2023 was a transformative year for Xtant Medical. We achieved record annual revenues of $91.3 million, up 58% year-over-year, on which we generated organic growth of 15% compared to the prior year," said Sean Browne, President and CEO of Xtant Medical. "Additionally, we successfully integrated three separate busines

      4/1/24 7:00:00 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Xtant Medical to Issue Fourth Quarter and Full Year 2023 Financial Results on April 1, 2024

      BELGRADE, Mont., March 21, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2023, before the open of the financial markets on Monday, April 1, 2024. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Monday, April 1 at 9:00 AM ET to review results. Conference Details:Conference Date: Monday, April 1, 2024 - 9:00 AM ETConference dial-in: 877-407-6184International dial-in: 201-389-08

      3/21/24 4:05:00 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Xtant Medical Announces Record Third Quarter Revenue of $25 Million

      BELGRADE, Mont., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the third quarter ended September 30, 2023. "Driven by strong organic growth of 18%, and contributions from our recent acquisitions, we achieved record third quarter revenue of $25 million, an increase of 73% year-over-year, and raised our 2023 revenue guidance range for the second consecutive quarter," said Sean Browne, President and CEO of Xtant Medical. "I am extremely proud of our team's efforts integrating Surgalign's hardware and biologic

      11/9/23 7:00:00 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Nantahala Capital Management, Llc claimed ownership of 68,394,000 shares (SEC Form 3)

      3 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)

      4/17/25 4:31:14 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Orbimed Advisors Llc sold $30,708,129 worth of shares (73,114,592 units at $0.42) (SEC Form 4)

      4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)

      4/14/25 7:14:36 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: Chief Operations Officer Schallenberger Mark A. was granted 173,469 shares, increasing direct ownership by 85% to 378,613 units (SEC Form 4)

      4/A - Xtant Medical Holdings, Inc. (0001453593) (Issuer)

      1/17/25 4:29:24 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Neils Scott C covered exercise/tax liability with 7,986 shares, decreasing direct ownership by 1% to 622,305 units (SEC Form 4)

      4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)

      1/17/25 4:18:09 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Browne Sean E covered exercise/tax liability with 105,442 shares, decreasing direct ownership by 5% to 2,190,942 units (SEC Form 4)

      4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)

      10/16/24 4:09:59 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Vizirgianakis Stavros G. was granted 748,648 shares, increasing direct ownership by 12% to 6,961,773 units (SEC Form 4)

      4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)

      8/19/24 5:01:54 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Mitchell-Keller Lori D was granted 162,162 shares, increasing direct ownership by 85% to 353,124 units (SEC Form 4)

      4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)

      8/19/24 4:57:05 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Mcnamara Robert was granted 162,162 shares, increasing direct ownership by 27% to 754,151 units (SEC Form 4)

      4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)

      8/19/24 4:49:21 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Beeson Jonn R. was granted 162,162 shares, increasing direct ownership by 82% to 359,391 units (SEC Form 4)

      4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)

      8/19/24 4:40:32 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Bakewell John K was granted 162,162 shares, increasing direct ownership by 27% to 755,888 units (SEC Form 4)

      4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)

      8/19/24 4:32:25 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Xtant Medical Holdings Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Xtant Medical Holdings Inc.

      SC 13D/A - Xtant Medical Holdings, Inc. (0001453593) (Subject)

      9/10/24 4:12:57 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Xtant Medical Holdings Inc. (Amendment)

      SC 13G/A - Xtant Medical Holdings, Inc. (0001453593) (Subject)

      2/13/24 5:10:19 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Xtant Medical Holdings Inc. (Amendment)

      SC 13D/A - Xtant Medical Holdings, Inc. (0001453593) (Subject)

      8/3/23 4:59:55 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Xtant Medical Holdings Inc. (Amendment)

      SC 13D/A - Xtant Medical Holdings, Inc. (0001453593) (Subject)

      5/5/23 11:14:45 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Xtant Medical Holdings Inc. (Amendment)

      SC 13G/A - Xtant Medical Holdings, Inc. (0001453593) (Subject)

      2/14/23 4:51:19 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by Xtant Medical Holdings Inc.

      SC 13D - Xtant Medical Holdings, Inc. (0001453593) (Subject)

      9/6/22 2:19:05 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Xtant Medical Holdings Inc. (Amendment)

      SC 13D/A - Xtant Medical Holdings, Inc. (0001453593) (Subject)

      8/30/22 4:37:12 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Xtant Medical Holdings, Inc. (Amendment)

      SC 13D/A - Xtant Medical Holdings, Inc. (0001453593) (Subject)

      4/9/21 4:36:06 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed

      SC 13G - Xtant Medical Holdings, Inc. (0001453593) (Subject)

      3/8/21 5:19:17 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Xtant Medical Holdings, Inc. (0001453593) (Subject)

      2/16/21 4:33:24 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Xtant Medical Holdings Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Xtant Medical to Issue First Quarter 2025 Financial Results on May 12, 2025

      BELGRADE, Mont., May 6, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic and woundcare disorders, today announced that it will release its financial results for the first quarter ended March 31, 2025, after the close of the financial markets on Monday, May 12, 2025. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Monday, May 12, 2025 at 4:30 PM ET to review results. Conference Details:Conference Date: Monday, May 12, 2025Conference Time: 4:30 PM ETConference dial-in: 888-506-0062International dial

      5/6/25 8:00:00 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Xtant Medical Launches Trivium™ Advanced Bone Graft for Superior Performance

      BELGRADE, Mont., April 23, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc.(NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic and woundcare disorders, is proud to announce the launch of Trivium™, a premium, next-generation demineralized bone matrix (DBM) allograft designed to elevate the standard of care in bone grafting procedures. Engineered with advanced PureLoc™ Fiber Technology, Trivium combines three synergistic elements intended to deliver exceptional performance in structure, handling, and biological activity.

      4/23/25 8:00:00 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Xtant Medical Announces Secondary Private Sale of Existing Shares by OrbiMed and Preliminary First Quarter 2025 Revenue Growth of 18% to 19%

      Healthcare Focused Long-term Investors Support Strategic Vision Accelerating Shift to Higher-Margin Orthobiologics Supported by New Product Launches BELGRADE, Mont., April 16, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic and woundcare disorders, today announced the completion of a secondary private sale of 73.1 million shares of Xtant common stock held by funds affiliated with OrbiMed Advisors LLC ("OrbiMed") to several existing and new stockholders, led by Nantahala Capital Management LLC ("Nantahala"). Sean Browne, President and CEO of Xtant Medical, stated, "We want

      4/16/25 8:05:00 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Xtant Medical Reports Third Quarter 2024 Financial Results

      Third Quarter Revenue Growth of 12%Reaffirms Full Year 2024 Revenue Guidance of $116 Million to $120 MillionRepresenting Growth of 27% to 31% BELGRADE, MT / ACCESSWIRE / November 12, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the third quarter ended September 30, 2024.Third Quarter 2024 Financial HighlightsRevenue of $27.9 million, up 12%, compared to the prior year quarter; year to date revenue of $85.8 million, up 36% compared to prior year periodGross margin of 58.4% compared to 61.3% for the prior year quarterNet loss of $5.0 mi

      11/12/24 4:05:00 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Xtant Medical to Attend the 15th Annual Craig-Hallum Alpha Select Conference

      BELGRADE, MT / ACCESSWIRE / November 11, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced announced that Sean Browne, CEO and Scott Neils, CFO will be attending the following upcoming conference:Event: 15th Annual Craig-Hallum Alpha Select ConferenceDate: November 19, 2024Location: Sheraton NY Times Square Hotel, New York, NYFormat: 1x1 MeetingsFor more information, please visit: https://www.meetmax.com/sched/event_110237/conference_home.html?bank_access=0&event_id=110237About Xtant Medical Holdings, Inc.Xtant Medical's mission of honoring the gift of donation so that our

      11/11/24 8:00:00 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Xtant Medical to Issue Third Quarter 2024 Financial Results on November 12, 2024

      BELGRADE, MT / ACCESSWIRE / November 7, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the third quarter ended September 30, 2024, after the close of the financial markets on Tuesday, November 12, 2024.Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Tuesday, November 12, 2024 at 4:30 PM ET to review results.Conference Details:Conference Date: Tuesday, November 12, 2024Conference Time: 4:30 PM ETConference dial-in: 888-999-3182International dial-in:

      11/7/24 10:45:00 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Xtant Medical Expands Product Portfolio with the Launch of the Cortera(R) Posterior Fixation System

      New System Enhances Surgical Efficiency and Provides Versatile Solutions for Complex Spine ProceduresBELGRADE, MT / ACCESSWIRE / September 23, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a leading global medical technology company focused on the treatment of spinal disorders, is excited to announce the launch of the Cortera Posterior Fixation System, a comprehensive solution designed to streamline thoracolumbar fixation surgeries. Now available to surgeons across the United States through Xtant's commercial channels., Cortera enhances surgical workflows while delivering value across a wide spectrum of complex spinal procedures."The Cortera Posterior Fixation System is a significant addi

      9/23/24 7:00:00 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Xtant Medical Expands Product Portfolio with Launch of its own Viable Bone Matrix, OsteoVive(R) Plus

      New Cellular Bone Matrix Designed with Cohesive and Moldable Handling Characteristics BELGRADE, MT / ACCESSWIRE / September 18, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced it has launched a new addition to its robust product portfolio, OsteoVive Plus, a moldable, viable bone matrix that can be used in a variety of grafting procedures. The graft is now available, to the company's nationwide distribution network of independent agents as well as original equipment manufacturer relationships.OsteoVive Plus Sean Browne, President and CEO of Xtant Medical, stated, "New

      9/18/24 6:00:00 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Xtant Medical Announces Closing of $5.0 Million Private Placement

      BELGRADE, MT / ACCESSWIRE / August 9, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the closing of its previously announced $5.0 million private placement with an existing institutional investor. The Company sold 7,812,500 shares of common stock at a purchase price of $0.64 per share. After deducting fees and other estimated offering expenses, the Company received net proceeds of approximately $4.6 million.The Company expects to use the net proceeds from the private placement for working capital and other general corporate purposes.Craig-Hallum acted as sole placement a

      8/9/24 4:05:00 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Xtant Medical Announces $5.0 Million Private Placement

      BELGRADE, MT / ACCESSWIRE / August 8, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced it has entered into a securities purchase agreement with an existing institutional investor to sell shares of its common stock in a private placement. The Company agreed to issue an aggregate of 7,812,500 shares of common stock at a purchase price of $0.64 per share, resulting in gross proceeds of $5.0 million.The Company expects to use the net proceeds from the private placement for working capital and other general corporate purposes. The closing of the private placement is expected to

      8/8/24 7:20:00 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Xtant Medical Holdings Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Apyx Medical Corporation Announces Board Leadership Transition

      Andrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors; Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the retirement of Andrew Makrides as Chairman of the Board, after serving the Company in this position since 1982. The Board of Directors has appointed Stavros Vizirgianakis Chairman of the Board, effective as of May 7, 2024. "On behalf of the entire organization, I would like to express our gratitude to Andrew for his lead

      5/9/24 7:00:00 AM ET
      $APYX
      $BVS
      $XTNT
      Medical/Dental Instruments
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Xtant Medical Appoints Lori Mitchell-Keller to Board of Directors

      BELGRADE, Mont., May 18, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the appointment of Lori Mitchell-Keller to the Company's Board of Directors effective May 16, 2023. Ms. Mitchell-Keller will serve as a member of the Compensation and Audit Committees of the Board of Directors. "We are pleased to welcome Lori to our Board, marking another high-quality independent member addition," said Stavros G. Vizirgianakis, Chairman of Xtant's Board of Directors. "Her deep operations, information technologies, and marketing expertise will be of significant va

      5/18/23 8:00:00 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Xtant Medical Appoints Mark Schallenberger as Chief Operations Officer

      BELGRADE, Mont., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the appointment of Mark Schallenberger as Chief Operations Officer, effective January 16, 2023. "We are thrilled to have Mark rejoin the team as we reinvent Xtant," said Sean Browne, President and Chief Executive Officer of Xtant Medical. "In this newly created role, Mark will drive the modernization of our production, lead the optimization of our processes and operations, and support the diversification and development of new product lines. We look forward to Mark's contributio

      1/9/23 8:00:00 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Xtant Medical Appoints Scott Neils as Chief Financial Officer

      BELGRADE, Mont., May 02, 2022 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the appointment of Scott Neils as Chief Financial Officer, effective June 1, 2022. "Scott's success and experience during his tenure at Xtant, including his recent position as interim Chief Financial Officer, makes him an invaluable member of our team," said Sean Browne, President and Chief Executive Officer of Xtant Medical. "Scott's continued contributions will be instrumental as we execute on our growth strategy and deliver on our mission of ‘honoring the gift of donation.'"

      5/2/22 8:00:00 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Xtant Medical Appoints Scott Neils Interim Chief Financial Officer

      BELGRADE, Mont., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the appointment of Scott Neils as Interim Chief Financial Officer succeeding Greg Jensen, the Company's current Vice President, Finance and Chief Financial Officer, effective January 3, 2022. "We are excited to announce this well deserved promotion for Scott. His demonstrated ability to oversee the Company's finance and accounting operations in his current role as the Company's Controller and his depth of experience in accounting will continue to be a great benefit to Xtant Me

      1/3/22 8:00:00 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • IMPULSE DYNAMICS APPOINTS FIVE NEW BOARD MEMBERS

      MARLTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting of its shareholders.  "We are extremely pleased to have Jim Tobin, Joe Capper, Glenn Muir, John Bakewell, and Dan Scavila all joining our board of directors," said Prof. Shlomo Ben-Haim, Chairman of the Board and Founder of Impulse Dynamics.  "This is an illustrious group to be adding to the board, and I am extremely pleased to be welcoming and working with all of them as we rapidly advance our goals for the company, for CCM therapy, and mo

      11/11/21 7:26:31 PM ET
      $BEAT
      $GMED
      $GTHX
      $HOLX
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Electronics